AccScience Publishing / BH / Online First / DOI: 10.36922/BH026020001
Submit to BH
Cite this article
17
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW ARTICLE

Caspase inhibition in neurodegenerative diseases: A new therapeutic frontier

Amaan Javed1* ,  Binish Javed2 ,  Saurab Karki3 ,  Anagha Shree4 ,  Zeba Sami4 ,  Jasneet Kaur5 ,  Sucharu Asri4
Show Less
1 University College of Medical Sciences, University of Delhi, Delhi, India
2 Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, Delhi, India
3 Nepal National Hospital, Kathmandu, Nepal
4 Shree Guru Gobind Singh Tricentenary Medical College and Research Institute, Gurugram, Haryana, India
5 Government Medical College, Amritsar, Punjab, India
Brain & Heart, 026020001 https://doi.org/10.36922/BH026020001
Received: 8 January 2026 | Revised: 20 March 2026 | Accepted: 24 March 2026 | Published online: 29 April 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
XML
Cite
Abstract

Apoptosis is defined as a form of programmed cell death that contributes to neuronal injury across a range of neurological disorders, including neurovascular and neurodegenerative diseases. It is governed by a group of cysteine proteases called caspases. Due to their significant role as signaling mediators, caspases have emerged as potential therapeutic targets. This review evaluates the current evidence on caspase involvement in neurodegeneration and explores caspase inhibition as a novel treatment approach. We performed a structured literature search from 2015 to 2025 across PubMed, Scopus, and Cochrane Central Register of Controlled Trials, supplemented by screening of ClinicalTrials.gov for interventional studies of caspase-modulating therapies in neurological disorders. We included full-text studies written in English that report neuronal outcomes and/or disease-relevant endpoints in the context of caspase inhibition or caspase-targeted modulation. Evidence was synthesized using narrative thematic analysis, stratified by disease category, caspase class, and regulated cell-death modality. Thirty-one eligible studies were included. Caspase-3 was implicated in 11 studies on Alzheimer’s disease, and caspases-1, 8, 9, and 12 were also reported in both Alzheimer’s and Parkinson’s disease. Multiple studies have reported elevated caspase activity in disease-affected brain regions and have demonstrated that pharmacological inhibition attenuated neuronal loss in preclinical models. Caspase dysregulation represents a convergent mechanism across neurodegeneration, spanning apoptosis, pyroptosis-related neuroinflammation, and pathway crosstalk. Therapeutic caspase inhibition remains promising but requires improved target selectivity, biomarker-guided trial design, and explicit evaluation of long-term risks given caspases’ homeostatic roles in neurons and immunity.

Keywords
Neurodegenerative diseases
Neuronal death
Caspases
Apoptotic inhibition
Funding
None.
Conflict of interest
The authors declare no conflict of interest.
References
  1. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell. 2004;117(5):561-574. doi: 10.1016/j.cell.2004.05.004
  2. Yan N, Shi Y. Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol. 2005;21(1):35-56. doi: 10.1146/annurev.cellbio.21.012704.131040
  3. Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 2004;384(2):201-232. doi: 10.1042/bj20041142
  4. Engidawork E, Gulesserian T, Yoo BC, Cairns N, Lubec G. Alteration of Caspases and Apoptosis-Related Proteins in Brains of Patients with Alzheimer’s Disease. Biochem Biophys Res Commun. 2001;281(1):84-93. doi: 10.1006/bbrc.2001.4306
  5. Friedlander RM. Apoptosis and Caspases in Neurodegenerative Diseases. N Engl J Med. 2003;348(14):1365-1375. doi: 10.1056/nejmra022366
  6. Espinosa-Oliva AM, García-Revilla J, Alonso-Bellido IM, Burguillos MA. Brainiac Caspases: Beyond the Wall of Apoptosis. Front Cell Neurosci. 2019;13. doi: 10.3389/fncel.2019.00500
  7. Park HY, Park JI, Baek DW, et al. Modulation of neutrophil apoptosis by β-amyloid proteins. Int Immunopharmacol. 2006;6(7):1061-1069. doi: 10.1016/j.intimp.2006.01.019
  8. Vito P, Ghayur T, D’Adamio L. Generation of Anti-apoptotic Presenilin-2 Polypeptides by Alternative Transcription, Proteolysis, and Caspase-3 Cleavage. J Biol Chem. 1997;272(45):28315-28320. doi: 10.1074/jbc.272.45.28315
  9. Yang ZH, Sun K, Suo WH, et al. N-stearoyltyrosine protects primary neurons from Aβ-induced apoptosis through modulating mitogen-activated protein kinase activity. Neuroscience. 2010;169(4):1840-1847. doi: 10.1016/j.neuroscience.2010.05.069
  10. Xie J, Guo Q, Zhu H, Wooten MW, Mattson MP. Protein kinase C iota protects neural cells against apoptosis induced by amyloid β-peptide. Mol Brain Res. 2000;82(1-2):107-113. doi: 10.1016/s0169-328x(00)00187-x
  11. Zhao S, Zhao J, Zhang T, Guo C. Increased apoptosis in the platelets of patients with Alzheimer’s disease and amnestic mild cognitive impairment. Clin Neurol Neurosurg. 2016;143:46-50. doi: 10.1016/j.clineuro.2016.02.015
  12. Song L, De Sarno P, Jope RS. Central Role of Glycogen Synthase Kinase-3β in Endoplasmic Reticulum Stress-induced Caspase-3 Activation. J Biol Chem. 2002;277(47):44701-44708. doi: 10.1074/jbc.m206047200
  13. Chen X, Chi S, Liu M, et al. Inhibitory effect of ganglioside GD1b on K+ current in hippocampal neurons and its involvement in apoptosis suppression. J Lipid Res. 2005;46(12):2580-2585. doi: 10.1194/jlr.m500252-jlr200
  14. Christie LA, Su JH, Tu CH, Dick MC, Zhou J, Cotman CW. Differential regulation of inhibitors of apoptosis proteins in Alzheimer’s disease brains. Neurobiol Dis. 2007;26(1):165- 173. doi: 10.1016/j.nbd.2006.12.017
  15. Hong Y, Liu Y, Yu D, Wang M, Hou Y. The neuroprotection of progesterone against Aβ-induced NLRP3-Caspase-1 inflammasome activation via enhancing autophagy in astrocytes. Int Immunopharmacol. 2019; 74:105669. doi: 10.1016/J.INTIMP.2019.05.054
  16. Marques CA, Keil U, Bonert A, et al. Neurotoxic Mechanisms Caused by the Alzheimer’s Disease-linked Swedish Amyloid Precursor Protein Mutation. J Biol Chem. 2003;278(30):28294-28302. doi: 10.1074/jbc.m212265200
  17. Rohn TT, Head E, Su JH, et al. Correlation between Caspase Activation and Neurofibrillary Tangle Formation in Alzheimer’s Disease. Am J Pathol. 2001;158(1):189-198. doi: 10.1016/s0002-9440(10)63957-0
  18. Yukioka F, Matsuzaki S, Kawamoto K, et al. Presenilin-1 mutation activates the signaling pathway of caspase-4 in endoplasmic reticulum stress-induced apoptosis. Neurochem Int. 2008;52(4-5):683-687. doi: 10.1016/j.neuint.2007.08.017
  19. Yu W, Mechawar N, Krantic S, Quirion R. Evidence for the Involvement of Apoptosis-Inducing Factor–Mediated Caspase-Independent Neuronal Death in Alzheimer Disease. Am J Pathol. 2010;176(5):2209-2218. doi: 10.2353/ajpath.2010.090496.
  20. Yoo JY, Kim HB, Baik TK, Lee JH, Woo RS. Neuregulin 1/ ErbB4/Akt signaling attenuates cytotoxicity mediated by the APP-CT31 fragment of amyloid precursor protein. Exp Mol Pathol. 2021;120:104622. doi: 10.1016/j.yexmp.2021.104622
  21. Zhang H, Liu Y, Lao M, Ma Z, Yi X. Puerarin protects Alzheimer’s disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways. Exp Gerontol. 2011;46(1):30-37. doi: 10.1016/j.exger.2010.09.013
  22. Olivera Santa-Catalina M, Caballero Bermejo M, Argent R, Alonso JC, Centeno F, Lorenzo MJ. JNK signaling pathway regulates sorbitol-induced Tau proteolysis and apoptosis in SH-SY5Y cells by targeting caspase-3. Arch Biochem Biophys. 2017;636:42-49. doi: 10.1016/j.abb.2017.11.004
  23. Jung EB, Lee CS. Baicalein attenuates proteasome inhibition-induced apoptosis by suppressing the activation of the mitochondrial pathway and the caspase-8- and Bid-dependent pathways. Eur J Pharmacol. 2014;730:116-124. doi: 10.1016/j.ejphar.2014.02.039
  24. Wani WY, Sunkaria A, Sharma DR, et al. Caspase inhibition augments Dichlorvos-induced dopaminergic neuronal cell death by increasing ROS production and PARP1 activation. Neuroscience. 2014;258:1-15. doi: 10.1016/j.neuroscience.2013.11.004
  25. Kang S, Piao Y, Kang YC, Lim S, Pak YK. DA-9805 protects dopaminergic neurons from endoplasmic reticulum stress and inflammation. Biomed Pharmacother. 2022;145:112389. doi: 10.1016/j.biopha.2021.112389
  26. Li Y, Sun L, Cai T, et al. α-Synuclein overexpression during manganese-induced apoptosis in SH-SY5Y neuroblastoma cells. Brain Res Bull. 2010;81(4-5):428-433.doi: 10.1016/j.brainresbull.2009.11.007
  27. Ren J, Yuan L, Wang W, et al. Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson’s disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway. Toxicol Appl Pharmacol. 2019;378:114617. doi: 10.1016/j.taap.2019.114617
  28. Li Q, Zhang P, Cai Y. Genkwanin suppresses MPP+- induced cytotoxicity by inhibiting TLR4/MyD88/NLRP3 inflammasome pathway in a cellular model of Parkinson’s disease. NeuroToxicology. 2021;87:62-69. doi: 10.1016/j.neuro.2021.08.018
  29. McDowell ML, Das A, Smith JA, Varma AK, Ray SK, Banik NL. Neuroprotective effects of genistein in VSC4.1 motoneurons exposed to activated microglial cytokines. Neurochem Int. 2011;59(2):175-184. doi: 10.1016/j.neuint.2011.04.011
  30. Jin ML, Park SY, Kim YH, Oh JI, Lee SJ, Park G. The neuroprotective effects of cordycepin inhibit glutamate-induced oxidative and ER stress-associated apoptosis in hippocampal HT22 cells. NeuroToxicology. 2014;41:102- 111. doi: 10.1016/j.neuro.2014.01.005
  31. Hao Y, Bai S, Peng J, et al. TRIM27-mediated ubiquitination of PPARγ promotes glutamate-induced cell apoptosis and inflammation. Exp Cell Res. 2021;400(1):112437. doi: 10.1016/j.yexcr.2020.112437
  32. Goffredo D, Rigamonti D, Zuccato C, Tartari M, Valenza M, Cattaneo E. Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington’s Disease. Pharmacol Res. 2005;52(2):140-150. doi: 10.1016/j.phrs.2005.01.006
  33. Kristiansen M, Messenger MJ, Klöhn PC, et al. Disease-related Prion Protein Forms Aggresomes in Neuronal Cells Leading to Caspase Activation and Apoptosis. J Biol Chem. 2005;280(46):38851-38861. doi: 10.1074/jbc.m506600200
  34. Stoica BA, Movsesyan VA, Lea IV PM, Faden AI. Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3β, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol Cell Neurosci. 2003;22(3):365-382. doi: 10.1016/s1044-7431(02)00028-3
  35. Koh SH, Kim SH, Kwon H, et al. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Mol. Brain Res. 2003;118(1-2):72-81. doi: 10.1016/j.molbrainres.2003.07.003
  36. Tian LL, Wang XJ, Sun YN, et al. Salvianolic acid B, an antioxidant from Salvia miltiorrhiza, prevents 6-hydroxydopamine induced apoptosis in SH-SY5Y cells. Int J Biochem Cell Biol. 2008;40(3):409-422. doi: 10.1016/j.biocel.2007.08.005
  37. Wang H, Zhao P, Huang Q, Chi Y, Dong S, Fan J. Bisphenol-A induces neurodegeneration through disturbance of intracellular calcium homeostasis in human embryonic stem cells-derived cortical neurons. Chemosphere. 2019;229:618- 630. doi: 10.1016/j.chemosphere.2019.04.099
  38. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet. 1993;341(8855):1251-1254. doi: 10.1016/0140-6736(93)91154-e
  39. Reed JC. Mechanisms of Apoptosis. Am J Pathol. 2000;157(5):1415-1430. doi: 10.1016/s0002-9440(10)64779-7
  40. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol. 2003;15(6):725-731. doi: 10.1016/j.ceb.2003.10.009
  41. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419(6905):395- 399. doi: 10.1038/nature01063
  42. Wang J, Zheng L, Lobito A, et al. Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II. Cell. 1999;98(1):47-58. doi: 10.1016/s0092-8674(00)80605-4
  43. McComb S, Chan PK, Guinot A, et al. Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7. Sci Adv. 2019;5(7). doi: 10.1126/sciadv.aau9433
  44. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002;7(4):313-319. doi: 10.1023/a:1016167228059
  45. Armstrong RC, Aja TJ, Hoang KD, et al. Activation of the CED3/ICE-Related Protease CPP32 in Cerebellar Granule Neurons Undergoing Apoptosis But Not Necrosis. J Neurosci. 1997;17(2):553-562. doi: 10.1523/jneurosci.17-02-00553.1997
  46. De Zio D, Giunta L, Corvaro M, Ferraro E, Cecconi F. Expanding roles of programmed cell death in mammalian neurodevelopment. Semin Cell Dev Biol. 2005;16(2):281- 294. doi: 10.1016/j.semcdb.2004.12.003
  47. D’Amelio M, Sheng M, Cecconi F. Caspase-3 in the central nervous system: beyond apoptosis. Trends Neurosci. 2012;35(11):700-709. doi: 10.1016/j.tins.2012.06.004
  48. Johnson D. Noncaspase proteases in apoptosis. Leukemia. 2000;14(9):1695-1703. doi: 10.1038/sj.leu.2401879
  49. Yagami T, Yamamoto Y, Koma H. Pathophysiological Roles of Intracellular Proteases in Neuronal Development and Neurological Diseases. Mol Neurobiol. 2018;56(5):3090- 3112. doi: 10.1007/s12035-018-1277-4
  50. Neumar RW, Xu YA, Gada H, Guttmann RP, Siman R. Cross-talk between Calpain and Caspase Proteolytic Systems During Neuronal Apoptosis. J Biol Chem. 2003;278(16):14162-14167. doi: 10.1074/jbc.m212255200
  51. Canu N, Barbato C, Ciotti MT, Serafino A, Dus L, Calissano P. Proteasome Involvement and Accumulation of Ubiquitinated Proteins in Cerebellar Granule Neurons Undergoing Apoptosis. J Neurosci. 2000;20(2):589-599. doi: 10.1523/jneurosci.20-02-00589.2000
  52. Cotman CW, Poon WW, Rissman RA, Blurton-Jones M. The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology. J Neuropathol Exp Neurol. 2005;64(2):104- 112. doi: 10.1093/jnen/64.2.104
  53. Kuida K. Caspase-9. Int. J. Biochem. Cell Biol. 2000;32(2):121- 124. doi: 10.1016/s1357-2725(99)00024-2
  54. Liu J, Liu W, Yang H. Balancing Apoptosis and Autophagy for Parkinson’s Disease Therapy: Targeting BCL-2. ACS Chem Neurosci. 2018;10(2):792-802. doi: 10.1021/acschemneuro.8b00356
  55. Lakkappa N, Krishnamurthy PT, Hammock BD, Velmurugan D, Bharath MMS. Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disorders. Med. Hypotheses. 2016;93:161-165. doi: 10.1016/j.mehy.2016.06.003
  56. Wang X, Chen S, Ma G, Ye M, Lu G. Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev. 2005;126(12):1241-1254. doi: 10.1016/j.mad.2005.06.012
  57. Erekat NS. Apoptosis and its Role in Parkinson’s Disease. In: Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; 2018:65-82. doi: 10.15586/codonpublications.parkinsonsdisease.2018. ch4
  58. Lev N, Melamed E, Offen D. Apoptosis and Parkinson’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27(2):245-250. doi: 10.1016/s0278-5846(03)00019-8
  59. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2010;1802(1):2-10. doi: 10.1016/j.bbadis.2009.10.006
  60. Roth KA. Caspases, Apoptosis, and Alzheimer Disease: Causation, Correlation, and Confusion. J Neuropathol Exp Neurol. 2001;60(9):829-838. doi: 10.1093/jnen/60.9.829
  61. Ming X, Li W, Maeda Y, et al. Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci. 2002;197(1-2):9-18. doi: 10.1016/s0022-510x(02)00030-8
  62. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821. doi: 10.1177/1352458520970841
  63. Eren E, Özören N. The NLRP3 inflammasome: a new player in neurological diseases. Turk J Biol. 2019;43(6):349-359. doi: 10.3906/biy-1909-31
  64. Khoshnam SE, Winlow W, Farzaneh M, Farbood Y, Moghaddam HF. Pathogenic mechanisms following ischemic stroke. Neurol Sci. 2017;38(7):1167-1186. doi: 10.1007/s10072-017-2938-1
  65. Broughton BRS, Reutens DC, Sobey CG. Apoptotic Mechanisms After Cerebral Ischemia. Stroke. 2009;40(5). doi: 10.1161/strokeaha.108.531632
  66. Nakka VP, Gusain A, Mehta SL, Raghubir R. Molecular Mechanisms of Apoptosis in Cerebral Ischemia: Multiple Neuroprotective Opportunities. Mol Neurobiol. 2007;37(1):7-38. doi: 10.1007/s12035-007-8013-9
  67. Hu BR, Liu CL. Mechanisms of Neuron Death (Necrosis, Apoptosis, Autophagy) After Brain Ischemia. In: Primer on Cerebrovascular Diseases. Elsevier; 2017:209-215. doi: 10.1016/b978-0-12-803058-5.00043-6
  68. Kuschinsky W, Gillardon F. Apoptosis and Cerebral Ischemia. Cerebrovasc Dis. 2000;10(3):165-169. doi: 10.1159/000016052
  69. Akamatsu Y, Hanafy KA. Cell Death and Recovery in Traumatic Brain Injury. Neurotherapeutics. 2020;17(2):446-456. doi: 10.1007/s13311-020-00840-7
  70. Thapa K, Khan H, Singh TG, Kaur A. Traumatic Brain Injury: Mechanistic Insight on Pathophysiology and Potential Therapeutic Targets. J Mol Neurosci. 2021;71(9):1725-1742. doi: 10.1007/s12031-021-01841-7
  71. Hiebert JB, Shen Q, Thimmesch AR, Pierce JD. Traumatic Brain Injury and Mitochondrial Dysfunction. Am J Med Sci. 2015;350(2):132-138. doi: 10.1097/maj.0000000000000506
  72. Zhang X, Chen Y, Jenkins LW, Kochanek PM, Clark RSB. Bench-to-bedside review: Apoptosis/programmed cell death triggered by traumatic brain injury. Crit Care. 2004;9(1):66. doi: 10.1186/cc2950
  73. Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052
  74. Wood LK, Langford SJ. Motor Neuron Disease: A Chemical Perspective. J Med Chem. 2014;57(15):6316-6331. doi: 10.1021/jm5001584
  75. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: A systematic review and meta‐analysis. Mov Disord. 2012;27(9):1083-1091. doi: 10.1002/mds.25075
  76. Ferreira IL, Nascimento MV, Ribeiro M, et al. Mitochondrial-dependent apoptosis in Huntington’s disease human cybrids. Exp Neurol. 2010;222(2):243-255. doi: 10.1016/j.expneurol.2010.01.002
  77. Zhang L, Yang H, Zhao H, Zhao C. Calcium-related signaling pathways contributed to dopamine-induced cortical neuron apoptosis. Neurochem Int. 2011;58(3):281-294. doi: 10.1016/j.neuint.2010.11.021
  78. WHO. Schizophrenia. Posted 2025. Available from: https:// www.who.int/news-room/fact-sheets/detail/schizophrenia [Last accessed on].
  79. Chen C, Dong XP. Epidemiological characteristics of human prion diseases. Infect Dis Poverty. 2016;5(1). doi: 10.1186/s40249-016-0143-8
  80. Ye L, Li G, Goebel A, et al. Caspase-11–mediated enteric neuronal pyroptosis underlies Western diet–induced colonic dysmotility. J Clin Investig. 2020;130(7):3621-3636. doi: 10.1172/jci130176
  81. Graham LC, Harder JM, Soto I, de Vries WN, John SWM, Howell GR. Chronic consumption of a western diet induces robust glial activation in aging mice and in a mouse model of Alzheimer’s disease. Sci Rep. 2016;6(1). doi: 10.1038/srep21568
  82. Poxleitner M, Hoffmann SHL, Berezhnoy G, et al. Western diet increases brain metabolism and adaptive immune responses in a mouse model of amyloidosis. J Neuroinflammation. 2024;21(1). doi: 10.1186/s12974-024-03080-0
  83. Więckowska-Gacek A, Mietelska-Porowska A, Wydrych M, Wojda U. Western diet as a trigger of Alzheimer’s disease: From metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration. Ageing Res Rev. 2021;70:101397. doi: 10.1016/j.arr.2021.101397

84. El Kebir D, Filep JG. Modulation of Neutrophil Apoptosis and the Resolution of Inflammation through β2 Integrins. Front Immunol. 2013;4. doi: 10.3389/fimmu.2013.00060

Share
Back to top
Brain & Heart, Electronic ISSN: 2972-4139 Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept